Topline data from two Phase III trials in neovascular or ‘wet’ age-related macular degeneration (nAMD) show Roche Holding AG’s investigational bispecific antibody faricimab is as effective as – but no better than – Bayer AG and Regeneron Pharmaceuticals, Inc.’s Eylea when dosed at fixed intervals of up to every 16 weeks.
Roche Prepares Faricimab For Filing After Phase III AMD Data
Non-Inferior To Eylea With Longer Dosing Intervals
Top-line Phase III data for faricimab in age-related macular degeneration leave Roche poised to file the bi-specific antibody for retinal diseases, but again there is no advantage with the novel dual-acting product over Eylea.
